
Keywords: ATIR; anti-tumor immune response; ATM; ataxia telangiectasia mutated; CDK; cyclin-dependent kinase; CGH; comparative genomic hybridization; CHK1; checkpoint kinase 1; CHK2; checkpoint kinase 2; DDAs; DNA-damaging agents; DDR; DNA damage response; DSBs; do